Dr. Nanette Y. Fabi, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 18127 William St, Lansing, IL 60438 Phone: 708-474-8844 Fax: 708-474-6135 |
News Archive
Celgene International Sà rl, a subsidiary of Celgene Corporation, (NASDAQ: CELG), announced final results from a phase II investigational study evaluating the combination of REVLIMID® (lenalidomide) and rituximab in 59 patients with relapsed or refractory chronic lymphocytic leukemia (CLL). These data were presented at the 53rd Annual Meeting of the American Society of Hematology in San Diego, CA.
A study in The Journal of Cell Biology reveals that the microRNA miR-7 suppresses gastric (stomach) cancer by inhibiting a key signaling pathway, and that this protective mechanism is compromised by the cancer-causing bacterium H. pylori. Finding drugs capable of inducing miR-7 could therefore prove to be an effective treatment against the progression of gastric cancer.
On January 11, 2010, U.S. Consumer Product Safety Commission Chairman Inez Tenenbaum issued a statement at the APEC Toy Safety Initiative Dialogue in Hong Kong, China, warning manufacturers against the use of cadmium, antimony and barium in lieu of lead in children's products.
The International Society for Cellular Therapy, the global society of clinicians, researchers, regulatory specialists, technologists, and industry partners dedicated to the translation of cellular therapy into safe and effective therapies to improve patients' lives, today announces its reasons for opposition to the current version of the REGROW Act - the US government's legislative efforts to promote faster patient access to effective new cellular therapies.
› Verified 1 days ago